Assenagon Asset Management S.A. Lowers Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Assenagon Asset Management S.A. lowered its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 63.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 114,618 shares of the specialty pharmaceutical company's stock after selling 196,999 shares during the period. Assenagon Asset Management S.A. owned 0.53% of ANI Pharmaceuticals worth $7,674,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. US Bancorp DE boosted its holdings in shares of ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after acquiring an additional 531 shares during the period. GAMMA Investing LLC grew its holdings in ANI Pharmaceuticals by 163.8% during the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after buying an additional 881 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter valued at about $166,000. Rafferty Asset Management LLC bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter valued at about $200,000. Finally, Bridgefront Capital LLC purchased a new stake in shares of ANI Pharmaceuticals in the fourth quarter worth about $204,000. 76.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, insider Christopher Mutz sold 4,000 shares of the company's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total transaction of $241,800.00. Following the completion of the transaction, the insider now owns 107,317 shares of the company's stock, valued at $6,487,312.65. This represents a 3.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Ori Gutwerg sold 881 shares of the company's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total value of $52,921.67. Following the transaction, the senior vice president now owns 89,897 shares of the company's stock, valued at approximately $5,400,112.79. This represents a 0.97% decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,681 shares of company stock valued at $346,854 in the last quarter. Company insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Trading Up 2.0%

ANI Pharmaceuticals stock traded up $1.24 during mid-day trading on Wednesday, hitting $64.59. The company's stock had a trading volume of 221,447 shares, compared to its average volume of 311,120. The company has a debt-to-equity ratio of 1.46, a current ratio of 2.66 and a quick ratio of 1.98. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of -50.81 and a beta of 0.55. The business has a 50 day moving average price of $64.71 and a 200-day moving average price of $61.17. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.33. The firm had revenue of $197.12 million during the quarter, compared to the consensus estimate of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. The business's revenue was up 43.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.82 earnings per share. As a group, analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Truist Financial increased their target price on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research note on Monday, April 21st. Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They set a "buy" rating and a $80.00 price objective on the stock. Guggenheim reaffirmed a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. JPMorgan Chase & Co. initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 target price for the company. Finally, Wall Street Zen downgraded ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $80.13.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.